Philip Rowe

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

Jonathan A. Ledermann, Philipp Harter, Charlie Gourley et al. · The Lancet Oncology · 2016 · 452 citations · Full text

Medicine, Gynecology, Oncology +17

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

Michael Friedländer, Ursula A. Matulonis, Charlie Gourley et al. · British Journal of Cancer · 2018 · 183 citations · Full text

Medicine, Oncology, Pharmacology +17

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

Sophie E. Willis, C Winkler, Martine P. Roudier et al. · British Journal of Cancer · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacology +14

Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

Charlie Gourley, Michael Friedländer, Ursula A. Matulonis et al. · Journal of Clinical Oncology · 2017 · 24 citations

Medicine, Oncology, Pharmacology +15

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

Monique B. Nilsson, Uma Giri, Jayanthi Gudikote et al. · Clinical Cancer Research · 2015 · 17 citations

Medicine, Oncology, Pharmacology +17